FDA Approves Moderna’s First mRNA Flu Vaccine
The FDA has approved Moderna's mRNA flu vaccine, marking the first of its kind in the nation.
Tampa St. Petersburg, FL, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s messenger RNA (mRNA) flu vaccine. This marks a significant development as it is the first mRNA-based influenza vaccine to receive authorization in the United States.
The approval signifies a new approach to influenza vaccination, utilizing mRNA technology, which has previously been prominent in COVID-19 vaccines. The specific details regarding the efficacy, target age groups, and timeline for availability of the new vaccine were not provided in the initial summary.
Moderna’s innovation in developing an mRNA flu vaccine could potentially alter the landscape of seasonal flu prevention. Further information regarding the vaccine’s performance in clinical trials, its manufacturing scale, and distribution plans is anticipated.
Story summarized from the original created by Nathaniel Weixel and The Hill on www.wfla.com, see more information here.
